Get the Stockscreener App
3.38
3.43%
-0.12
Agenus Inc stock is traded at $3.38, with a volume of 769.85K.
It is down -3.43% in the last 24 hours and up +98.82% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$3.50
Open:
$3.54
24h Volume:
769.85K
Relative Volume:
1.30
Market Cap:
$80.70M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0491
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
+13.80%
1M Performance:
+98.82%
6M Performance:
+11.55%
1Y Performance:
-69.52%
1-Day Range:
$3.201
$3.67
1-Week Range:
$2.83
$4.0597
52-Week Range:
$1.38
$19.69
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.38 | 80.70M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
Analyst Reiterates Neutral Rating for Agenus (AGEN) | AGEN Stock News - GuruFocus
Agenus (AGEN) Target Price Raised by Analyst Baird | AGEN Stock News - GuruFocus
Agenus (AGEN) Receives Price Target Increase from Baird | AGEN S - GuruFocus
Agenus Inc. (NASDAQ:AGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
Agenus names Dr Richard Goldberg as CDO - Medical Buyer
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges - Yahoo Finance
Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Mo - GuruFocus
Agenus Inc. Reports Q1 2025 Progress and Financials - TipRanks
Agenus Inc. Earnings Call: Optimism Amid Challenges - TipRanks
Agenus signals near-term strategic transactions and operational cash burn target below $50M amid BOT/BAL data advances - MSN
Agenus (AGEN) Moves to Sell 165,000 Shares of Common Stock - GuruFocus
Agenus (AGEN) Registers Plan to Offer 165,000 Common Shares | AG - GuruFocus
Agenus: Q1 Earnings Snapshot - MySA
Agenus appoints oncology veteran Dr. Goldberg as CDO By Investing.com - Investing.com Canada
Agenus (AGEN) Sets Strategic Path with New Leadership and Transactions - GuruFocus
Agenus reports Q1 EPS ($1.03), consensus ($1.98) - TipRanks
Transcript : Agenus Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Agenus reports Q1 2025 net loss, stock rises premarket - Investing.com
Agenus (AGEN) Reports Strong Q1 Revenue Surpassing Expectations - GuruFocus
Agenus (AGEN) Reports Q1 Earnings, Beats EPS Estimates - GuruFocus
Agenus Inc (AGEN) Q1 2025 Earnings: EPS Beats Estimates at -$1.0 - GuruFocus
Agenus Reports Q1 2025 Financial Results and Key Business Updates | AGEN Stock News - GuruFocus
AGEN Welcomes Renowned Cancer Expert Dr. Richard Goldberg as Chi - GuruFocus
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer | AGEN Stock News - GuruFocus
Dr. Richard Goldberg Joins Agenus as Chief Development Officer - citybiz
Renowned Gi Oncology Leader Dr. Richard Goldberg Joins Agenus As Chief Development Officer - marketscreener.com
Agenus Reports Q1 2025 Financial Results and Key Business Updates - Stock Titan
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer - Eagle-Tribune
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Re - GuruFocus
Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Agenus (AGEN) Set for Q1 Earnings Release with Optimistic EPS Revisions - GuruFocus
Lost Money on Agenus Inc. (AGEN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors Who Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class ActionAGEN - ACCESS Newswire
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report | AGEN Stock News - GuruFocus
Agenus To Provide Corporate Update And First Quarter 2025 Financial Report - marketscreener.com
Agenus to Reveal Q1 2025 Financial Performance and Strategic Updates: Key Details for Investors - Stock Titan
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report - Bluefield Daily Telegraph
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Stu - GuruFocus
Breakthrough: Agenus BOT/BAL Cancer Treatment Achieves 90% Response Rate Across Multiple Tumors - Stock Titan
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AAC - GuruFocus
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 - The Joplin Globe
New Clinical Data: Agenus' BOT/BAL Achieves 72% Disease Control Rate in Treatment-Resistant Liver Cancer - Stock Titan
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):